Home › Funds › Birchview Capital, LP › RLMD
Birchview Capital, LP position in RLMD
RELMADA THERAPEUTICS INC · Health Care
Birchview Capital, LP reported holding 408,100 shares of RLMD (RELMADA THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$1.5M, representing 0.92% of its reported portfolio and ranking #28 among its reported holdings. Birchview Capital, LP has disclosed RLMD holdings in 3 of the last 3 reported quarters, going back to Q1 2026.
Last updated: 2026-11-14 · Source: SEC EDGAR Form 13F-HR
How Birchview Capital, LP's RLMD position evolved
Birchview Capital, LP first disclosed a stake in RLMD in Q1 2026 at 409,387 shares (US$2.8M). Across 3 filings, Birchview Capital, LP held the position steady without any share-count change. The most recent filing (Q3 2026) shows 408,100 shares valued at US$1.5M.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2026 | 409.39K | $2.85M | New |
| Q2 2026 | 408.10K | $2.82M | Hold |
| Q3 2026 | 408.10K | $1.54M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About RLMD and 13F data
RLMD (RELMADA THERAPEUTICS INC) is a Health Care company. 70 other funds we track also report a position in RLMD — the largest reported positions include Squadron Capital Management LLC (US$50.9M), Venrock Adviser, LLC (US$47.4M), Spruce Street Capital LP (US$26.1M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding RLMD
- Squadron Capital Management LLC 7.35M sh · $50.86M · Q2 2026
- Venrock Adviser, LLC 6.84M sh · $47.36M · Q2 2026
- Spruce Street Capital LP 6.91M sh · $26.06M · Q3 2026
- Jones Hill Capital LP 5.24M sh · $19.75M · Q3 2026
- Ikarian Capital, LLC 2.15M sh · $14.87M · Q2 2026
- STEMPOINT CAPITAL LP 1.46M sh · $10.10M · Q2 2026
- Commodore Capital LP 1.43M sh · $9.86M · Q2 2026
- Sio Capital Management, LLC 1.00M sh · $6.94M · Q2 2026
- Opaleye Management Inc. 935.00K sh · $6.47M · Q2 2026
- Boxer Capital Management, LLC 842.11K sh · $5.83M · Q2 2026
- GREAT POINT PARTNERS LLC 842.11K sh · $5.83M · Q2 2026
- AdvisorShares Investments LLC 670.86K sh · $2.53M · Q3 2026
More on Birchview Capital, LP
FAQ
How long has Birchview Capital, LP held RLMD?
Birchview Capital, LP has disclosed RLMD holdings in 3 of the last 3 reported quarters, going back to Q1 2026.
What is Birchview Capital, LP's current position in RLMD?
As of Q3 2026, Birchview Capital, LP holds 408.10K shares of RLMD (RELMADA THERAPEUTICS INC), valued at $1.54M, representing 0.92% of its reported portfolio and ranking #28.
Has Birchview Capital, LP been buying or selling RLMD?
In the latest 13F filing (Q3 2026), Birchview Capital, LP held unchanged its position in RLMD.
Which other funds hold RLMD?
Other major institutional holders of RLMD include Squadron Capital Management LLC, Venrock Adviser, LLC, Spruce Street Capital LP, among 70 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.